| Similar Articles |
|---|
 |
The Motley Fool
August 18, 2010
Travers & Jayson |
Interested in Elan? Start Here! You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big.   |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
The Motley Fool
August 27, 2010
Travers & Jayson |
The Most Important Thing about Regeneron Pharmaceuticals Stop obsessing about the science. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will Onyx Pharmaceuticals Burn You? Is Onyx Pharmaceuticals on strong financial footing? |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
August 18, 2010
Travers & Jayson |
The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up? |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
January 26, 2005
Stephen D. Simpson |
The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities. |
The Motley Fool
October 31, 2005
Charly Travers |
A Myriad of Shares Management's predilection for excessive share dilution at Myriad Genetics is troubling for investors. |
The Motley Fool
November 30, 2004
Charly Travers |
Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks. |
The Motley Fool
November 16, 2004
Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
The Motley Fool
August 22, 2006
Brian Gorman |
NICE Unkind to Biotech Developments in the U.K.'s drug coverage may hurt U.S. biotechs. Biotech investors, keep your eyes on this issue. |
The Motley Fool
January 12, 2005
Charly Travers |
Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
August 23, 2005
W.D. Crotty |
A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look? |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
The Motley Fool
February 27, 2007
Brian Lawler |
Three Strikes for Telik Investors, there's not much in the pipeline at this small biotech company. |
The Motley Fool
August 2, 2004
Charly Travers |
What's a Drug Worth? The value of small biotech companies is in their investigational drug programs. |
The Motley Fool
March 22, 2005
Charly Travers |
Do Good Drugs Guarantee Investment Success? By the time you know a drug is good, are you late to the party? Instead of trying to catch a train that has already zipped by, try investing in drug programs well in advance of phase 3 trials. |
The Motley Fool
February 9, 2006
Stephen D. Simpson |
Serono: On the Block and on the Clock Will the Swiss-based biotech be able to strike a good deal for shareholders? |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
July 14, 2005
Charly Travers |
Dueling Fools: Protein Design Labs Bull Rebuttal This biotech's tomorrow is coming today. The company is a clear buy at its current market cap near $2 billion. |
The Motley Fool
January 13, 2011
Seth Jayson |
Does Novo Nordisk Measure Up? With recent TTM margins all exceeding historical averages, Novo Nordisk looks like it's doing fine. |
The Motley Fool
August 28, 2006
Brian Lawler |
The Commandments of Biotech Investing Since long-term successful biotech investing requires accurate risk assessment, you must be aware of the risk you're taking on. Just as with any prospective investment, if you diversify your biotech holdings, you can somewhat mitigate these various risks. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
The Motley Fool
September 10, 2008
Brian Orelli |
Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
October 16, 2006
Brian Lawler |
The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
May 19, 2004
Roger Nusbaum |
Gilead Shines This biotech company looks strong because investors can relate to its products. |
